⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ESLA News
Estrella Immunopharma, Inc. Common Stock
Form 8-K
sec.gov
ESLAW
ESLA
Estrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion Phase
businesswire.com
ESLA
Form 8-K
sec.gov
ESLAW
ESLA
Form 8-K
sec.gov
ESLA
ESLAW
Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
businesswire.com
ESLA
Form 8-K
sec.gov
ESLAW
ESLA
Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT ® & CIBMTR ®
businesswire.com
ESLAW
ESLA
Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
businesswire.com
ESLA
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation
businesswire.com
ESLA
Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients
businesswire.com
ESLA